Maria Stepanova1,2, Zobair M Younossi3,4. 1. Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA. 2. Betty and Guy Beatty Center for Integrated Research, Inova Health System, Claude Moore Health Education and Research Building, 3300 Gallows Road, Falls Church, VA, 22042, USA. 3. Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA. zobair.younossi@inova.org. 4. Betty and Guy Beatty Center for Integrated Research, Inova Health System, Claude Moore Health Education and Research Building, 3300 Gallows Road, Falls Church, VA, 22042, USA. zobair.younossi@inova.org.
Abstract
BACKGROUND: Recently developed interferon- and ribavirin-free regimens to treat hepatitis C virus infection (HCV) have low side effect profile accompanied by high efficacy. AIM: To assess the potential access to these regimens using the most recent data on candidacy and insurance coverage for HCV-positive Americans. METHODS: The National Health and Nutrition Examination Survey (NHANES) cycles 2005-2008 and 2009-2012 were used in this cross-sectional study. RESULTS: A total of 10,799 and 11,840 adult (18+) NHANES participants were included from the two cycles, respectively. Of these, 1.19 and 0.94%, respectively, showed detectable viremia (HCV+). The proportion of HCV+ individuals aged ≥65 increased from 1.7 to 6.8% (p = 0.0144). HCV+ individuals were less likely to be insured than HCV- regardless of the study year (HCV+: 63.8% vs. HCV-: 80.1%, p = 0.0005). Between the study cycles, the rates of insurance coverage (60.2 and 67.4%, respectively) and treatment eligibility based on medical contraindications for interferon-based treatment (66.6 and 74.1%, respectively) were not different (p > 0.05). With minimal contraindications for interferon- and ribavirin-free treatment, 95.1 and 97.7% of HCV+ patients could be eligible for treatment despite aging of the study population and unchanged rates of comorbid conditions. Considering both treatment eligibility and insurance coverage, potential access to anti-HCV treatment increased from 35.1% for interferon-based to 66.6% for interferon-free regimens (p = 0.0003). CONCLUSIONS: A large proportion of HCV+ individuals remain uninsured or under-insured. The lack of adequate coverage limits their access to the newly developed interferon- and ribavirin-free regimens for HCV that are highly effective with minimal contraindications.
BACKGROUND: Recently developed interferon- and ribavirin-free regimens to treat hepatitis C virus infection (HCV) have low side effect profile accompanied by high efficacy. AIM: To assess the potential access to these regimens using the most recent data on candidacy and insurance coverage for HCV-positive Americans. METHODS: The National Health and Nutrition Examination Survey (NHANES) cycles 2005-2008 and 2009-2012 were used in this cross-sectional study. RESULTS: A total of 10,799 and 11,840 adult (18+) NHANES participants were included from the two cycles, respectively. Of these, 1.19 and 0.94%, respectively, showed detectable viremia (HCV+). The proportion of HCV+ individuals aged ≥65 increased from 1.7 to 6.8% (p = 0.0144). HCV+ individuals were less likely to be insured than HCV- regardless of the study year (HCV+: 63.8% vs. HCV-: 80.1%, p = 0.0005). Between the study cycles, the rates of insurance coverage (60.2 and 67.4%, respectively) and treatment eligibility based on medical contraindications for interferon-based treatment (66.6 and 74.1%, respectively) were not different (p > 0.05). With minimal contraindications for interferon- and ribavirin-free treatment, 95.1 and 97.7% of HCV+ patients could be eligible for treatment despite aging of the study population and unchanged rates of comorbid conditions. Considering both treatment eligibility and insurance coverage, potential access to anti-HCV treatment increased from 35.1% for interferon-based to 66.6% for interferon-free regimens (p = 0.0003). CONCLUSIONS: A large proportion of HCV+ individuals remain uninsured or under-insured. The lack of adequate coverage limits their access to the newly developed interferon- and ribavirin-free regimens for HCV that are highly effective with minimal contraindications.
Entities:
Keywords:
Direct-acting antiviral agents; Health services accessibility; Hepatitis C; Interferon
Authors: David B Rein; John S Wittenborn; Bryce D Smith; Danielle K Liffmann; John W Ward Journal: Clin Infect Dis Date: 2015-03-16 Impact factor: 9.079
Authors: Mina Kabiri; Alison B Jazwinski; Mark S Roberts; Andrew J Schaefer; Jagpreet Chhatwal Journal: Ann Intern Med Date: 2014-08-05 Impact factor: 25.391
Authors: Alexis P Chidi; Cindy L Bryce; Julie M Donohue; Michael J Fine; Douglas P Landsittel; Larissa Myaskovsky; Shari S Rogal; Galen E Switzer; Allan Tsung; Kenneth J Smith Journal: Value Health Date: 2016-03-24 Impact factor: 5.725
Authors: Vasily Isakov; Igor Nikitin; Vladimir Chulanov; Pavel Ogurtsov; Ekaterina Lukyanova; Jianmin Long; Janice Wahl; Frans A Helmond Journal: World J Hepatol Date: 2016-02-28
Authors: Zaki A Sherif; Mehdi Nouraie; Rehana Begum; Ali Afsari; Babak Shokrani; Edward Lee; Adeyinka O Laiyemo; Hassan Brim; Hassan Ashktorab Journal: Medicine (Baltimore) Date: 2020-04 Impact factor: 1.817
Authors: Lauren E Cipriano; Shan Liu; Kaspar S Shahzada; Mark Holodniy; Jeremy D Goldhaber-Fiebert Journal: Med Decis Making Date: 2018-08-22 Impact factor: 2.583
Authors: Monika Sarkar; Jennifer L Dodge; Ruth M Greenblatt; Mark H Kuniholm; Jack DeHovitz; Michael Plankey; Andrea Kovacs; Audrey L French; Eric C Seaberg; Igho Ofotokun; Margaret Fischl; Edgar Overton; Erin Kelly; Peter Bacchetti; Marion G Peters Journal: Clin Infect Dis Date: 2017-10-30 Impact factor: 9.079
Authors: Zobair M Younossi; Louis L LaLuna; John J Santoro; Flavia Mendes; Victor Araya; Natarajan Ravendhran; Lisa Pedicone; Idania Lio; Fatema Nader; Sharon Hunt; Andrei Racila; Maria Stepanova Journal: BMC Gastroenterol Date: 2016-04-04 Impact factor: 3.067